bluebird bio (BLUE) Late-Breaker ASH Abstract Provides Proof-Of-Concept - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Wedbush Affirms bluebird bio (BLUE) at 'Outperform'; Late-Breaking ASH Data Bodes Will for bb2121
November 16, 2015 12:40 PM ESTWedbush affirms bluebird bio (Nasdaq: BLUE) with an Pit[erfpr, ratomg amd $165 price target after the company reported Phase 1 results in a late-breaking abstract from a NCI-sponsored study of anti-BCMA CAR-T cells dosed in multiple myeloma patients.
Analyst David M. Nierengarten noted, At lower doses (0.3-1 x 106 cells), 1 patient demonstrated a partial response (PR)... More
